Adam Simpson, Icosavax CEO
May 23, 2023 07:16 AM EDTUpdated 08:55 AM
Financing
R&D

Icosavax push­es for­ward com­bo RSV-hM­PV vac­cine and an­nounces di­rect stock of­fer­ing

Katherine Lewin

News Reporter

Seat­tle-based Icosavax may have failed in its at­tempt at a Covid-19 vac­cine in 2022, but it re­leased ear­ly da­ta on its bi­va­lent vac­cine can­di­date for …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

BioN­Tech set­tles with NIH, UPenn in Covid vac­cine dis­putes and will pay roy­al­ties

FDA ap­proves sub­cu­ta­neous ver­sion of Bris­tol My­er­s' Op­di­vo

J&J part­ners on STAT6; As­traZeneca, Dai­ichi with­draw lung can­cer drug EMA app

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Ca­griSe­ma’s weight loss da­ta dis­ap­point­ed. What does No­vo do next?

Ac­cel­er­at­ed ap­proval brings Pfiz­er's BRAF in­hibitor to first-line pa­tients

A service from the Financial Times